Biomarkers in the Diagnosis and Prognosis of NAFLD

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

September 22, 2025

Study Completion Date

September 22, 2026

Conditions
NAFLDObesityLiver FibrosisDiabetes Mellitus, Type 2
Interventions
DIAGNOSTIC_TEST

Plasma Test

IGF-2 (insulin-like growth factor 2)

DIAGNOSTIC_TEST

Plasma test

SPARC (secreted protein acidic and rich in cysteine)

DIAGNOSTIC_TEST

Plasma test

EPICAN (heparan sulfate proteoglycan)

DIAGNOSTIC_TEST

Plasma test

EGFR (epidermal growth factor receptor)

DIAGNOSTIC_TEST

Liver biopsy

Fibrosis and steatosis grade according to Brunt-Kleiner classification

DIAGNOSTIC_TEST

Visceral adipose tissue biopsy

Presence of inflammation

DIAGNOSTIC_TEST

Liver elastography

Grade of fibrosis according to Hamaguchi score

DIAGNOSTIC_TEST

Blood test

Determination of surrogate based diagnostic tests/scores for liver fibrosis

Trial Locations (1)

34100

RECRUITING

Silvia Palmisano, Trieste

All Listed Sponsors
lead

University of Trieste

OTHER